Anti-Inflammatory Characteristics of Local Anesthetics: Inhibition of TNF-α Secretion of Lipopolysaccharide-Stimulated Leucocytes in Human Blood Samples.
LPS
clinical study
cytokines
local anesthetics
neural therapy
tumor necrosis factor-alpha
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
02
12
2021
revised:
11
03
2022
accepted:
14
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Background. Local anesthetics (LAs) have potent anti-inflammatory properties. Inflammatory down-regulation is crucial in diseases with overactive immune reactions, such as acute respiratory distress syndrome (ARDS) and chronic inflammation. We investigated the influence of four LAs, procaine, lidocaine, mepivacaine, and bupivacaine, on the reduction of tumor necrosis factor-alpha (TNF-α) secretion in lipopolysaccharide (LPS)-activated human leucocytes. Methods. Blood samples of 28 individuals were stimulated with LPS. The reduction of TNF-α production by each of the four LAs added (0.5 mg/mL) was measured and correlated with biometric variables. A response was defined as reduction to <85% of initial levels. Results. All four LAs down-regulated the TNF-α secretion in 44−61%: Bupivacaine (44.4%), lidocaine (61.5%), mepivacaine (44.4%), and procaine (50% of the individuals, “responders”). The TNF-α secretion was reduced to 67.4, 68.0, 63.6, and 67.1% of the initial values in responders. The effects in both patients and healthy persons were the same. Interindividual responses to LAs were not correlated with the duration or type of complaints, basal TNF-α serum level, sex, BMI, or age of responders. Conclusions. Four clinically relevant LAs (amid-LA and ester-LA) attenuate the inflammatory response provoked by LPS. They are potential candidates for drug repositioning in treating overactive immune reactions and chronic inflammation.
Identifiants
pubmed: 35328706
pii: ijms23063283
doi: 10.3390/ijms23063283
pmc: PMC8949497
pii:
doi:
Substances chimiques
Anesthetics, Local
0
Anti-Inflammatory Agents
0
Lipopolysaccharides
0
Tumor Necrosis Factor-alpha
0
Procaine
4Z8Y51M438
Lidocaine
98PI200987
Mepivacaine
B6E06QE59J
Bupivacaine
Y8335394RO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Science. 2013 Jan 18;339(6117):286-91
pubmed: 23329041
J Pharmacol Exp Ther. 2001 Sep;298(3):996-1000
pubmed: 11504795
Mol Med Rep. 2014 Jan;9(1):118-24
pubmed: 24247931
Anesthesiology. 2000 Sep;93(3):858-75
pubmed: 10969322
Scand J Immunol. 2004 Oct;60(4):412-20
pubmed: 15379866
J Hepatol. 2003 Mar;38(3):289-97
pubmed: 12586294
BMJ. 2003 Jan 4;326(7379):41-4
pubmed: 12511463
Pain Med. 2020 Feb 1;21(2):401-414
pubmed: 31282958
Int Immunopharmacol. 2016 Apr;33:48-54
pubmed: 26854576
Br J Anaesth. 2006 Jan;96(1):77-87
pubmed: 16299047
J Nutr. 2003 Jul;133(7):2171-5
pubmed: 12840173
Acta Anaesthesiol Scand. 1996 Mar;40(3):318-25
pubmed: 8721462
J Neurophysiol. 2013 Apr;109(7):1704-12
pubmed: 23303863
Immunobiology. 2010 Apr;215(4):304-13
pubmed: 19559500
Br J Anaesth. 2014 Feb;112(2):370-9
pubmed: 24065730
Clin Exp Immunol. 2008 May;152(2):320-7
pubmed: 18355353
J Immunol. 2006 Sep 15;177(6):4086-93
pubmed: 16951373
Pharmacol Toxicol. 2002 Apr;90(4):173-80
pubmed: 12076310
Nat Rev Drug Discov. 2009 Jun;8(6):480-99
pubmed: 19483709
Acta Anaesthesiol Scand. 2006 Mar;50(3):265-82
pubmed: 16480459
Anesthesiology. 2002 Dec;97(6):1451-7
pubmed: 12459671
Int J Immunopharmacol. 1994 Apr;16(4):295-300
pubmed: 8045669
Anesthesiology. 2004 Apr;100(4):852-60
pubmed: 15087620
Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
pubmed: 18432654
Anesthesiology. 2012 Sep;117(3):548-59
pubmed: 22846676
Pancreas. 2011 Jul;40(5):673-9
pubmed: 21562445
Acta Anaesthesiol Scand. 1993 Feb;37(2):159-65
pubmed: 8383401
Ann Surg. 2007 Aug;246(2):192-200
pubmed: 17667496
Anesthesiology. 2000 Aug;93(2):497-509
pubmed: 10910501
J Surg Res. 2014 Nov;192(1):150-62
pubmed: 24952412
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Reg Anesth Pain Med. 2013 Jan-Feb;38(1):9-15
pubmed: 23222364
Anesth Analg. 2014 Oct;119(4):815-828
pubmed: 25036372
Mol Cell. 2008 Feb 15;29(3):279-90
pubmed: 18280234
J Pharmacol Exp Ther. 2003 Jul;306(1):84-92
pubmed: 12660311
Mol Immunol. 2018 May;97:94-100
pubmed: 29609129
Br J Anaesth. 2020 Oct;125(4):e391-e394
pubmed: 32792138
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Mol Pharmacol. 2001 Feb;59(2):294-301
pubmed: 11160866
Cell Death Differ. 2006 May;13(5):816-25
pubmed: 16410796
Mol Biol Rep. 2009 May;36(5):1113-7
pubmed: 18575957
J Formos Med Assoc. 2005 Oct;104(10):715-23
pubmed: 16385373
Mol Pharmacol. 2021 Nov;100(5):502-512
pubmed: 34475108
Int J Immunopharmacol. 1999 Dec;21(12):799-814
pubmed: 10606001
Pulm Pharmacol Ther. 2005;18(1):49-54
pubmed: 15607127